Docket No.: GNE.3230R1C1



## INFORMATION DISCLOSURE STATEMENT

icant

Goddard, et al.

App. No

10/006,867

Filed

December 6, 2001

For

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

Examiner

David J. Blanchard

Art Unit

1643

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 5, 2005

(Date)

AnneMarie Kaiser, Reg No. 37,64

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 20 references to be considered by the Examiner. Also enclosed are 20 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

12/12/2005 WABDELR1 00000079 10006867

01 FC:1806

180.00 OP

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

2165241:120505

PTO/SB/08 Equivalent 10/006,867 Application No. December 6, 2001 Filing Date Goddard, et al. First Named Inventor 1643 Art Unit David J. Blanchard Examiner (Multiple sheets used when necessary) GNE.3230R1C1 Attorney Docket No. SHEET 1 OF 2

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
	·					

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	WO 97/38085	10-16-1997	California Pacific Medical Center		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	itam (book magazina journal cerial cymnocium catalog etc.) date nade(s) Vollime-Issile	
	2	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 1216-1217. New York: Garland Publishing.	
	3	ANDERSON, et al. 1997. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis, 18:533-537.	
	4	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular &amp; Cellular Proteomics 1.4</i> , pp. 304-313.	
	5	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
	6	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , 15(16):4392-4401.	
	7	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. Pathology Associates Medical Laboratories.	
	8	HYMAN, et al. 2002. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Research, 62:6240-6245.	
	9	JANG, et al. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastatis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> , 15(5):469-483. (Abstract).	
	10	LABAER, Joshua. 2003. Letter to the editor: Mining the literature and large datasets. <i>Nature Biotechnology</i> , 21(9):976-977.	
	11	LIAN, et al. 2001. Genomic and proteomic analysis of the myeloid differentiation program. <i>Blood</i> , 98(3):513-524.	
	12	LICHTINGHAGEN, et al. 2002. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. <i>European Urology</i> , 42:398-406.	

Exami	ner	Sigr	nature	)

**Date Considered** 

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	13	ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular &amp; Cellular Proteomics</i> , 1:37-45.	
	14	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	
	15	POWELL, et al. 1998. Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , 8:411-421. (Abstract).	
-	16	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.	
	17	VALLE, et al. 2003. New approaches for biomarker discovery in lung cancer. <i>Expert Rev. Mol. Diagn.</i> , 3(1):55-67.	
	18	VALLEJO, et al. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. Biochimie, 82(12):1129-1133. (Abstract).	
	19	WANG, et al. 2002. Novel candidate tumor marker genes for lung adenocarcinoma. <i>Oncogene</i> , 21:7598-7604.	
	20	YOUSEF, et al. 2003. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Research, 63:2223-2227.	

INTORMATION DISCLOSURE

(Multiple sheets used when necessary)
SHEET 2 OF 2

T BY APPLICANT

2165204 120505

Examiner Signature

Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.